MicroMed Cardiovascular Appoints Deanne Yartz to Chief Financial Officer
Published: Sep 24, 2007
Ms. Yartz is an operationally oriented financial executive with experience in all aspects of financial reporting, Sarbanes-Oxley compliance, best practices implementation, acquisition and disposition transaction evaluation, negotiation, and financial management.
Since 2003, she served as financial consultant with Sirius Solutions, LLP. From 1998 to 2004, Ms. Yartz was an independent consultant for various private and publicly traded companies. Prior to that, she was the VP of Finance and Chief Financial Officer of WNS, Inc. from 1986-1998. Ms. Yartz holds a BBA degree from the University of Texas and is a Certified Public Accountant.
"Ms. Yartz will bring significant financial experience to the company," said Bob Benkowski, CEO of MicroMed. "Her professional experience and expertise will serve MicroMed well as we enter an exciting period for the company and the industry."
About MicroMed Cardiovascular, Inc.
The DeBakey VAD® is a miniaturized ventricular assist device (VAD) which was jointly developed by the famed heart surgeon Dr. Michael E. DeBakey, Dr. George Noon, and the National Aeronautics and Space Administration (NASA). The DeBakey VAD® is an implantable axial flow device designed to provide long-term, improved quality of life for patients who suffer from severe heart failure. It is the only device that provides accurate, real-time flow measurement improving the clinicians' patient care. It is CE-Mark approved in Europe for Bridge-to-Transplant (BTT), Destination Therapy (DT), and pediatric use with the DeBakey VAD® Child. The DeBakey VAD® is undergoing an IDE BTT clinical study in the U.S. and the DeBakey VAD® Child is the only FDA approved (HDE) pediatric ventricular assist device.
Forward-looking statements in this release regarding MicroMed Cardiovascular, Inc. are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, continued acceptance of the company's products, increased levels of competition, new products and technological changes, the company's dependence upon third-party suppliers, intellectual property rights and other risks detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission.
Contact Allison K. Wehner Marketing and Corporate Communications Coordinator Phone: (713) 580-8270 Fax: (713) 838-9214 Email Contact
Source: MicroMed Cardiovascular, Inc.